Bivalent Oral Polio Vaccine (bOPV)

BIOLOGICAL3 trials

Sponsors

Fidec Corporation, PATH, International Centre for Diarrhoeal Disease Research, Bangladesh

Conditions

PolioPoliomyelitis

Phase 1

Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults

CompletedNCT04232943

Start: 2020-01-22End: 2021-02-01Updated: 2022-09-06

Phase 4

Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine

CompletedNCT01831050

Fidec CorporationPoliomyelitis

Start: 2013-05-31End: 2014-12-31Target: 1420Updated: 2015-08-06

Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)

Not yet recruitingNCT06748612

International Centre for Diarrhoeal Disease Research, BangladeshPolio

Start: 2025-01-28End: 2027-12-30Target: 1190Updated: 2024-12-27

Related Papers

Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.

2023-02-044 citations

Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.

2017-04-257 citations

Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.

2016-05-1963 citations